Radiopharmaceutical Pluvicto, Locametz, Lutathera and Netspot Injections
ID: HT941026N0009Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCY HCD WESTCAMP PENDLETON, CA, 92055, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Set Aside

No Set aside used (NONE)

Original Source

https://sam.gov/workspace/contract/opp/b40721d0e963459baf855bb2f6c9a4b1/view
Timeline
    Description

    The Defense Health Agency (DHA) is planning to award a sole source, firm fixed-price Blanket Purchase Agreement to Novartis Pharmaceuticals Corporation for the provision of radiopharmaceutical injections, specifically Pluvicto, Locametz, Lutathera, and Netspot, for use at the Nuclear Medicine Division of the Naval Medical Center San Diego and other Medical Treatment Facilities. These injections are critical for emergency treatments, and the contract will be executed under the NPC FSS Contract: 36F79720D0180, as Novartis is deemed the only source capable of fulfilling the government's requirements. The period of performance for this contract is set from January 5, 2026, to January 4, 2031, and while this notice does not solicit competitive proposals, interested vendors may submit capability statements by December 9, 2026, to contest the sole source determination. For further inquiries, vendors can contact CHA-ON Gordon at cha-on.p.gordon2.civ@health.mil or Tracy Robinson at tracy.m.robinson18.civ@health.mil.

    Files
    Title
    Posted
    HT941026N0009 NOI Radiopharmaceutical Pluvicto Locametz Lutathera and Netspot Injections Multiple MTFs.pdf
    The Defense Health Agency Contracting Activity (DHACA) intends to award a sole source, firm fixed-price 5-year Blanket Purchase Agreement to Novartis Pharmaceuticals Corporation for radiopharmaceutical injections including Pluvicto, Locametz, Lutathera, and Netspot. These injections are for the Nuclear Medicine Division at Naval Medical Center San Diego (NMCSD) and other Medical Treatment Facilities, for emergency treatments. The award will be made under NPC FSS Contract: 36F79720D0180, following FAR 13.501(a) and 13.1061(b)(1)(i), as Novartis is identified as the only source capable of meeting the government's requirements. The period of performance is from January 5, 2026, to January 4, 2031. This notice is not a request for competitive proposals; however, interested vendors may submit capability statements by December 9, 2026, to challenge the sole source basis. Submissions should demonstrate the ability to provide the required customized implants, with the government retaining discretion on whether to proceed with a competitive procurement or sole source purchase.
    Lifecycle
    Title
    Type
    Radiopharmaceutical Pluvicto, Locametz, Lutathera and Netspot Injections
    Currently viewing
    Special Notice
    Similar Opportunities
    Notice of Intent to Award Sole Source to California Department of Public Health
    Buyer not available
    The Department of Defense, through the Defense Health Agency (DHA), intends to award a sole source contract to the California Department of Public Health for Newborn Screening Services. This procurement is essential for supporting the Naval Medical Center San Diego, Naval Hospital Camp Pendleton, and Navy Medicine Training Center Twentynine Palms, as mandated by various legislative requirements. The contract will be a Commercial, Firm-Fixed-Price Indefinite Delivery Indefinite Quantity (IDIQ) agreement, with the agency identifying only one responsible source that can meet its needs. Interested parties may submit bids or proposals for consideration, with inquiries directed to Jessica Medina at jessica.l.medina21.civ@health.mil by December 17, 2025, at 1600 PST. The applicable NAICS Code is 621511, with a business size standard of $41.5 million.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    6505--Positron Emission Tomography (PET) Radiopharmaceuticals for the Albany VA Medical Center
    Buyer not available
    The Department of Veterans Affairs is seeking qualified contractors to provide Positron Emission Tomography (PET) Radiopharmaceuticals for the Albany VA Medical Center. This procurement is structured as a five-year, firm fixed-price, Indefinite Delivery, Indefinite Requirements (IDIQ) contract, which includes a 12-month base period and four 12-month option periods. The required radiopharmaceuticals include F18 FDG Fluorodeoxyglucose, F18 NaF Sodium Fluoride, Pylarify (piflufolastat F18), Neuroceq (florbetaben F18), and Flyrcado (flurpiridaz F18), all essential for patient care in the Nuclear Medicine Department. Interested contractors must be licensed by the United States Nuclear Regulatory Commission (NRC) and the Food and Drug Administration (FDA) to manufacture and distribute these products in New York State, with responses due by 12:00 PM Eastern Standard Time on December 8, 2025. For further inquiries, contractors can contact Jonathan Kilgore, the Contracting Officer, at jonathan.kilgore@va.gov or by phone at 973-676-1000.
    Notice of Intent to Sole Source - Automated Call Distribution (ACD) System at Navy Medicine Readiness and Training Command (NMRTC) Naples, IT
    Buyer not available
    The Defense Health Agency (DHA) intends to award a sole source contract for an Automated Call Distribution (ACD) System at the Navy Medicine Readiness and Training Command (NMRTC) in Naples, Italy. This procurement aims to modernize and streamline the call management process for the NMRTC Naples Call Center, requiring capabilities such as automated call routing, integration with existing VOIP infrastructure, and compliance with HIPAA and DOD cybersecurity standards. The contract will be awarded to MCS of Tampa, Inc., unless other capable sources are identified, with capability statements due by 1600 hours EDT on December 5, 2025, submitted via email to Benjamin Reichlin at benjamin.s.reichlin.civ@health.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is soliciting quotes for pharmaceutical agents as part of its Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) through the Defense Health Agency (DHA). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs to determine their classification within the formulary. The P&T Committee will review newly approved drugs, including agents for pulmonary, gynecological, endocrine, atopy, skeletal muscle relaxants, and pain management, with quotes due by December 9, 2025, ahead of the committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Stephanie Erpelding or Tracy Banks for further details and ensure compliance with submission requirements outlined in the RFQ HT9402-26-Q-9102.
    Ondansetron Orally Disintegrating Tablets
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is seeking quotations for pharmaceutical agents as part of the Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP) to support the Military Health System (MHS). This procurement aims to establish an effective pharmacy benefits program by evaluating the clinical and cost-effectiveness of various pharmaceutical agents, including oncological and antihemophilic agents, for inclusion in the DoD Uniform Formulary. Interested manufacturers must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.
    Notice of Intent to Sole Source Virtual Reality Simulator Eyesi Surgical Complete System for Naval Medical Center San Diego
    Buyer not available
    The Defense Health Agency (DHA) intends to award a sole source contract to Haag-Streit USA, Inc. for the procurement of a Virtual Reality Simulator Eyesi Surgical Complete System for the Ophthalmology and Refractive Surgery Department at Naval Medical Center San Diego (NMCSD). This acquisition aims to replace a non-functional simulator that is critical for Graduate Medical Education (GME) and patient safety, allowing residents to practice microsurgical skills in a controlled environment, thereby reducing risks associated with live surgeries. The Eyesi simulator is uniquely validated for cataract and vitreoretinal surgeries and includes a curriculum aligned with GME standards, ensuring residents receive adequate training before performing surgeries on actual patients. Interested parties may submit capability statements by January 21, 2025, with the delivery of the simulator required by March 1, 2025. For further inquiries, contact Jennifer Collins at jennifer.e.collins23.civ@health.mil or Kennette Esguerra at kennette.m.esguerra.civ@health.mil.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Justification and Approval for Sole Source award for Portfolio and Resource Management Division (PRMD) Infrastructure and Service Resource Management Branch (ISRMB) Support Services.
    Buyer not available
    The Department of Defense, through the Defense Health Agency (DHA), is seeking to award a sole source contract for support services related to the Portfolio and Resource Management Division (PRMD) Infrastructure and Service Resource Management Branch (ISRMB). This procurement aims to secure essential management support services that are critical for the effective operation and oversight of the DHA's resource management initiatives. The contract, referenced as HT001123C0069, underscores the importance of specialized support in enhancing the efficiency of defense health operations. Interested parties can reach out to Saera Khan at saera.khan.civ@health.mil or 703-681-6507, or Erwin Rivera at erwin.rivera.civ@health.mil or 703-681-4300 for further details.